Home / Stocks / Glenmark Pharmaceuticals
GLENMARK

Glenmark Pharmaceuticals Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹2,608.5

Change

-37.6 (-1.42%)

Open

₹2,655.8

Prev. Close

₹2,646.1

Day High

₹2,666.7

Day Low

₹2,608.5

Volume Analysis

Traded

392,816

Delivered

192,198

Delivery %

48.93%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (23.6%)
  • •Strong operating margin (21.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year EPS growth (66.1%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,705.5 ₹2,686.1 ₹2,647.3 ₹2,627.9 ₹2,589.1 ₹2,569.7 ₹2,530.9
Fibonacci ₹2,686.1 ₹2,663.87 ₹2,650.13 ₹2,627.9 ₹2,605.67 ₹2,591.93 ₹2,569.7
Camarilla ₹2,624.51 ₹2,619.17 ₹2,613.84 ₹2,627.9 ₹2,603.17 ₹2,597.83 ₹2,592.5

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+28.74%

1 Week

-1.93%

1 Month

+18.89%

3 Months

+12.54%

6 Months

+15.47%

1 Year

+38.9%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹656.57

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

13.73%

Net margin 9.1% × asset turnover 0.79x × equity multiplier 1.91x

Company Overview

Sector

Healthcare

Market Cap

₹73,937 Cr

P/E (TTM)

36.5

ROE

23.6%

Book Value

₹397.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Glenmark Pharmaceuticals holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 71/100. The strongest factor is Financial Strength (100/100), while Valuation (20/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (23.6%); strong operating margin (21.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

71/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

62

Valuation

20

Cash Flow

73

Corporate Governance

73

Momentum

89

Institutional Ownership

60

Business Quality

84

Risk & Volatility

81

Liquidity

58

From Screener.in

  • +Company has reduced debt.
  • +Company has delivered good profit growth of 19.4% CAGR over last 5 years
  • −The company has delivered a poor sales growth of 9.19% over past five years.
  • −Company has a low return on equity of -3.28% over last 3 years.
  • −Debtor days have increased from 85.2 to 107 days.
  • −Working capital days have increased from 41.2 days to 80.5 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Glenmark USA launched authorized generic axitinib tablets, 1 mg and 5 mg, on November 16, 2026.

Glenmark to hold investor meetings in Taiwan, Singapore and Switzerland from 16-11-2026 to 23-11-2026.

Glenmark schedules investor meetings in Taiwan, Singapore, and Switzerland on 16-18 Nov and 23 Nov 2026.

Glenmark schedules investor meetings in Taiwan, Singapore and Switzerland during 16-11-2026 to 23-11-2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 3,207 2,507 3,063 3,244 3,434 3,388 3,256 3,264 6,047 3,901 3,771 4,018 4,247
Expenses + 2,745 2,715 2,559 2,656 2,832 2,787 2,695 2,684 3,687 3,031 3,008 3,214 3,384
Operating Profit 462 -209 504 588 602 600 561 581 2,360 870 763 805 864
OPM % 14.0% -8.0% 16.0% 18.0% 18.0% 18.0% 17.0% 18.0% 39.0% 22.0% 20.0% 20.0% 20.0%
Other Income + -205 87 351 31 39 31 -361 -297 -1,184 -140 -184 66 -281
Interest 121 134 149 40 48 52 67 58 66 41 43 54 64
Depreciation 141 147 151 118 120 123 125 130 141 154 148 173 180
Profit before tax -6 -403 555 462 473 456 8 96 967 534 388 643 338
Tax % 997.0% -18.0% 319.0% 26.0% 25.0% 24.0% 45.0% 51.0% 37.0% 24.0% 22.0% 25.0% 22.0%
Net Profit + -62 -331 -1,214 340 354 348 4 47 610 403 301 483 264
EPS in Rs -3 -12 -43 12 13 12 0 2 22 14 11 17 9
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 6 -19 2 7 7 35 6 1 76 15 16 23 -30

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 6,563 7,562 9,079 9,074 9,865 10,641 10,944 12,305 11,583 11,813 13,322 16,983 15,937
Expenses + 5,348 6,125 7,043 7,457 8,280 8,942 8,860 9,978 9,948 10,618 10,970 12,410 12,636
Operating Profit 1,214 1,437 2,037 1,617 1,586 1,699 2,084 2,327 1,635 1,195 2,351 4,572 3,301
OPM % 18.0% 19.0% 22.0% 18.0% 16.0% 16.0% 19.0% 19.0% 14.0% 10.0% 18.0% 27.0% 21.0%
Other Income + -180 20 -44 89 375 191 95 -101 -10 336 -259 -1,805 -540
Interest 190 179 237 286 335 377 353 298 349 516 207 209 202
Depreciation 300 234 264 302 326 417 444 487 569 582 486 573 656
Profit before tax 544 1,044 1,491 1,119 1,301 1,096 1,382 1,441 707 434 1,399 1,985 1,903
Tax % 61.0% 29.0% 26.0% 28.0% 29.0% 29.0% 30.0% 31.0% 47.0% 430.0% 25.0% 31.0% —
Net Profit + 209 743 1,109 804 925 776 970 994 377 -1,434 1,047 1,362 1,451
EPS in Rs 8 26 39 28 33 28 34 33 11 -53 37 48 51
Dividend Payout % 26.0% 8.0% 5.0% 7.0% 6.0% 9.0% 7.0% 7.0% 24.0% -5.0% 7.0% 10.0% —
Sales growth 9 15 20 0 9 8 3 12 -6 2 13 27 0

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 1,756 3,601 4,464 5,135 5,577 6,042 7,036 9,058 9,446 7,820 8,821 10,484 11,184
Borrowings + 3,800 3,988 4,724 4,639 4,449 4,869 4,986 3,962 4,608 1,231 2,473 594 1,407
Other Liabilities + 2,726 2,575 2,548 2,793 3,235 3,729 3,524 4,003 5,289 5,279 4,669 8,801 8,780
Total Liabilities 8,309 10,193 11,764 12,595 13,289 14,668 15,575 17,052 19,371 14,358 15,991 19,907 21,400
Fixed Assets + 2,015 2,594 2,755 3,030 3,670 5,029 5,129 5,887 5,422 4,210 4,487 5,915 6,385
CWIP 477 543 708 1,122 1,399 1,222 1,382 1,010 1,190 662 835 909 599
Investments 17 17 16 15 30 25 25 50 45 790 56 42 42
Other Assets + 5,799 7,039 8,285 8,429 8,190 8,393 9,040 10,105 12,715 8,697 10,613 13,041 14,373
Total Assets 8,309 10,193 11,764 12,595 13,289 14,668 15,575 17,052 19,371 14,358 15,991 19,907 21,400
Equity Capital 27 28 28 28 28 28 28 28 28 28 28 28 28

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 482 345 657 1,648 1,324 1,392 1,131 1,109 625 -265 -828 3,445
Cash from Investing Activity + -712 -950 -1,001 -1,003 -883 -774 -662 -316 -515 4,387 58 -1,237
Cash from Financing Activity + 199 699 543 -468 -739 -445 -442 -520 -77 -3,906 787 -2,709
Net Cash Flow -31 93 199 177 -297 174 28 272 32 215 17 -501
Free Cash Flow -56 -544 -76 625 712 616 456 320 75 -1,162 -1,576 2,090
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 66 57 67 124 111 109 79 72 77 65 -6 92

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 46.65% → 46.65%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 18.7% 18.58% 18.42% 17.06% 15.96% 15.56% 15.05% 13.97% 14.02% 13.7% 13.81% 14.17%
Promoters 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.64% 46.64% 46.65% 46.65% 46.65% 46.65%
Government 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04%
FII 23.71% 21.38% 20.98% 23.05% 23.51% 23.15% 20.62% 20.73% 19.2% 20.35% 20.89% 21.51%
DII 10.92% 13.36% 13.93% 13.21% 13.85% 14.6% 17.64% 18.61% 20.09% 19.28% 18.6% 17.63%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Glenmark Pharmaceuticals (this stock) 73,937 36.5 6.59 23.6%
Aster Dm Quality Care Ltd 63,907 122.0 8.2 11.3%
Alkem Laboratories Ltd. 61,875 28.6 4.16 18.9%
Fortis Healthcare Ltd 61,047 56.9 5.81 11.2%
Biocon Limited. 58,962 86.5 1.69 1.4%
Manipal Health Enterpri L 89,630 95.6 5.36 12.7%
Lupin Limited 89,994 16.0 3.75 28.7%

Which Mutual Funds Hold Glenmark Pharmaceuticals?

Frequently Asked Questions about Glenmark Pharmaceuticals

Community Sentiment

What are other investors saying about Glenmark Pharmaceuticals?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.